Plerith works with high growth start-ups and scaling companies to plan for and deliver growth. The company asserts that it helps companies promote their business to potential funders, through its network of angel and venture capital investors depending on the stage and sector of the said business. Plerith is partnering with Newable and Bristol Private Equity Club to deliver the fund in the South West London (SWL) area and identify and invest in the most exciting high growth companies in the region. Plerith argues that its deep knowledge of fundraising, sales, strategy, finance and technology would help SWL businesses flourish. Plerith aims to provide investors access to the highest quality local companies in the SWL region.
days to go:
Stretch
investment:
Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go:
TBC
investment:
£127,001
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go:
Extended
investment:
£295,000
Studio Pictures Ltd is a UK-based film and TV production company founded by producers Adam Rolston and David Braithwaite in 2019. Specializing in creating high-quality British entertainment content, the company focuses on adapting books to screen and telling unique true-life stories that entertain and inspire both domestic and international audiences. With successful productions like "A Street Cat Named Bob," the company is building a strong brand and reputation in the industry. Studio Pictures has access to top creative talent and collaborates with major studios like Warner Bros, Sony Pictures, Lionsgate, and Studio Canal. The company is located at Twickenham Studios in Richmond, UK.
days to go:
14
investment:
Withheld
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go:
Extended
investment:
Withheld
Alter Vego (AV) aims to create an extensive range of plant-based, customisable supplements. The company asserts that its production process is sustainable. It starts by creating a vegan protein base blend from ingredients such as pea, hemp, quinoa and brown rice that is ethically sourced and produced. It then develops daily sachets that contain Omega 3, B12, D3, K1, digestive enzymes, and probiotics to complement the base blend. AV argues that the sachets provide 100% of a user's Recommended Dietary Allowance (RDA) over any pre-mixed bulk blend. It aspires to become a contender in the global nutrition sector worth $702 billion. AV will use the investment for manufacturing and marketing its products across the UK.
days to go:
Expired
investment:
£46,455
An artificially intelligent web-based app for stock market investors to potentially increase their returns. Butterwire's platform aims to solve three common challenges more than 1 million UK investors face: finding high-return opportunities, minimising risk and being aware of sudden market fluctuations.
days to go:
Expired
investment:
Withheld
Monva is a financial technology platform that uses Artificial Intelligence (AI) to revolutionise the price comparison experience and personalise customer offers. It argues that only 38% of people in the UK trust Price Comparison Websites (PCWs) with the majority being wary of such entities. Monva aims to change that. Its AI Chatbot ‘Mo’ helps customers save time by suggesting search queries, highlighting key information to assist in making switching decisions, and providing alerts to new automated offers. The company has raised £625,000 in 2020 from DBW, Angels and crowdfunding sites. It was also overfunded by >200%. It aims to become a contender in the price comparison market valued at £2.8 billion. It will use the investment to continue building its smart comparison technology, secure commercial partnerships, and grow its marketing activity.
days to go:
Expired
investment:
£451,905
Centaur Robotics is redefining mobility for the 10% of the global population who require assistance to walk 400 meters. Representing a £7 billion global opportunity, the company offers a blend of convenient service and innovative two-wheeled vehicle design, catering to individuals and collaborating with international brands in sectors such as airlines, shopping centers, retirement living, hotels, and restaurants.
After a successful 2020 investment round, Centaur Robotics is currently seeking the final £65,000 of its seed equity round. This funding will facilitate pre-production market trials, design refinements, large-scale testing, and production expansion. With established commercial traction, the company aims for a full commercial launch by June 2024.
days to go:
Expired
investment:
£795,101
Avida Global (AG) is a Business-to-Business (B2B) producer of high-quality medicinal cannabis oils and derivatives for the global medical, well-being and cosmeceutical markets. The company has a cultivation and processing facility in North-East Colombia. It asserts that the therapeutic properties of the cannabis plant has driven 53 countries to legalise its use, with more to follow. AG seeks to capture this demand and become a contender in the medicinal cannabis market that is expected to soar from $33.1 billion to $84.0 billion by 2028. The company has received regulatory approvals for initial non-psychoactive cannabis cultivation, manufacturing, and export licences in 2019. It is working on a partnership with a medicinal cannabis prescriber through doctors and clinics for the supply of medicinal cannabis strains in the UK. The company will use 40% of the investment to drive revenue growth, 25% as capital expenses, and 35% as additional operating expenses.
days to go:
Expired
investment:
£1,646,249
